Impact of baseline and newly acquired conduction disorders on need for permanent pacemakers with 3 consecutive generations of self-expanding transcatheter aortic heart valves by Kroon, H.G. (Herbert G.) et al.
Cardiovascular Revascularization Medicine xxx (xxxx) xxx
CARREV-02259; No of Pages 6
Contents lists available at ScienceDirect
Cardiovascular Revascularization MedicineImpact of baseline and newly acquired conduction disorders on need for
permanent pacemakers with 3 consecutive generations of
self-expanding transcatheter aortic heart valvesHerbert G. Kroon, Lennart van Gils, Francesca Ziviello, Maarten van Wiechen, Joris Ooms, Zouhair Rahhab,
Nahid El Faquir, Anne-Marie Maugenest, Isabella Kardys, Joost Daemen,
Peter P. de Jaegere, Nicolas M. Van Mieghem ⁎
Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the NetherlandsAbbreviations: TAVR, Transcatheter aortic valve r
pacemaker implantation; THV, Transcatheter heart valve
Self-expanding valve; AV, Atrioventricular; STS, Society o
degree atrioventricular block; LBBB, Left bundle branch bl
block; LVOT, Left ventricular outflow tract; AF, Atrial fibril
⁎ Corresponding author at: Department of Interventio
ErasmusMC, Room Nt-645, Dr. Molewaterplein 40, 3015 G
E-mail address: n.vanmieghem@erasmusmc.nl (N.M. V
https://doi.org/10.1016/j.carrev.2021.01.025
1553-8389/© 2021 The Author(s). Published by Elsevi
Please cite this article as: H.G. Kroon, L. van
permanent pacemakers with 3 c..., Cardiovasa b s t r a c ta r t i c l e i n f oArticle history:
Received 18 September 2020
Received in revised form 11 December 2020
Accepted 22 January 2021
Available online xxxx
Keywords:




Early dischargeIntroductions: We aimed to compare conduction dynamics and need for permanent pacemaker implantation
(PPI) after CoreValve, Evolut R and PRO (transcatheter aortic valve replacement (TAVR)).
Methods: Patientswere stratified based on conduction at baseline; Cohort A had normal conduction, Cohort B had
conduction abnormalities including atrioventricular (AV)-block, fascicular block or complete bundle branch
block. Three different dynamic QRS-patterns were defined: stable QRS-duration, transient QRS-prolongation
and persistent QRS-prolongation. We performed multivariable regression analysis to estimate the effect of the
three separate transcatheter heart valves (THV's) on need for PPI at 30 days.
Results: TAVRwas performedwith CoreValve (N=113), Evolut R (N=157) or Evolut PRO (N=92). Conduction
dynamics were similar between the different THVs. Overall, Evolut R and PRO showed a tendency towards less
PPI compared to CoreValve (17% vs. 19% vs. 27%, P = 0.08), which was driven by a lower PPI rate in Cohort A
(6% vs. 11% vs. 25%, P = 0.002). Need for PPI was restricted to patients with persistent QRS-prolongation in Co-
hort A (26/106) but did not correlate with conduction dynamics in Cohort B. In multivariable logistic regression
analysis the use of Evolut R (OR 0.38, 95% CI 0.19–0.78, P=0.008) and PRO (OR 0.41, 95% CI 0.19–0.91, P-value=
0.028) were independently associated with less need for PPI.
Conclusion: The newer generations Evolut R and PRO were associated with less PPI compared to CoreValve.
Acquired persistent conduction abnormalities predicted PPI after TAVR only in patients with normal conduction
at baseline. Our findings may help identify eligible patients for early discharge after Evolut R/PRO TAVR.
© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Recently, studies have confirmed non-inferiority of transcatheter
aortic valve replacement (TAVR) in patients at low risk for surgery
[1,2]. Still, conduction abnormalities and need for permanent pace-
maker implantation (PPI) remain frequent after TAVR because of device
protrusion into the left ventricular outflow tract and consequent pres-
sure onto the atrioventricular (AV) node and His bundle [3,4]. PPI iseplacement; PPI, Permanent
; ECG, Electrocardiogram; SEV,
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cular Revascularization Medimore frequent with the self-expanding compared to balloon-
expandable transcatheter heart valve (THV) [3–7]. The 2nd generation
Evolut R THV (Medtronic Inc., Minneapolis, USA) introduced partial
recapturability and repositionability to optimize implantation depth
and limit paravalvular leakage and need for PPI and three consecutive
studies reported <20% PPI rates in their initial clinical experience with
Evolut R THV [8–10]. The Evolut PRO is the latest iteration adding a peri-
cardial wrap to furtherminimize paravalvular leakage [11].With trends
of shorter length of hospital stay and expanding TAVR indications to-
wards younger and lower risk patients, a cautious approach towards
conduction dynamics post-TAVR is paramount. Several studies reported
safety and feasibility of early discharge protocols. Patients with no
newly acquired persistent conduction disturbances after TAVR seemed
suitable for safe early discharge with no risk for late conduction issues
[12,13]. These studies included 1st generation mechanically expanded,
balloon expandable and self-expanding THV's and lacks confirmationcle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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aimed to compare conduction dynamics and need for PPI after TAVR
among 3 consecutive generations of self-expanding THV's.
2. Methods
All consecutive patients who underwent transfemoral or
transsubclavian TAVRwith 3 generations of self-expanding THV's for se-
vere aortic valve stenosis (AS) between January 2012 and December
2018 in our center were entered in a dedicated prospective database.
All patients provided written informed consent for the TAVR procedure
and subsequent data analysis for research purposes. This present study
was complementary with the Declaration of Helsinki and approved by
the Erasmus University Medical Center Rotterdam Institutional Review
Board. Patients with a pacemaker at baseline, who diedwithin 72 h post
TAVR or who had no electrocardiogram (ECG) data during their admis-
sion were excluded from the analysis.
2.1. Electrocardiogram analysis and conduction dynamics
The methodology of ECG analysis has been previously described in
detail [13]. In short, twelve‑lead electrocardiograms were collected at
baseline the day before TAVR and daily afterwards up to discharge, as
well as at the one-month follow-upvisit in the outpatient clinic. Patients
were stratified based on conduction at baseline into Cohort A with nor-
mal conduction and Cohort Bwith any conduction abnormality (any de-
gree AV-block, fascicular block or complete bundle branch block).
Dedicated clinical researchers (HK, LVG) analyzed all ECGs and an expe-
rienced interventional cardiologist (NVM) was consulted in case of dis-
crepancy. Only ECGs without temporary pacemaker intrusion were
analyzed for rhythm, conduction times, and the presence of atrioven-
tricular block or bundle branch block. We analyzed the ECG with the
longest QRS-duration, when multiple ECG's were present.
Conduction dynamics after TAVR were divided into three QRS-
patterns, as previously described by our group [13]:
1. Stable QRS-pattern: QRS-prolongation after TAVR ≤20 ms OR more
than 20 ms but never exceeding a total QRS-duration of 120 ms
throughout the admission.
2. Transient QRS-prolongation: QRS-prolongation >20 ms post-TAVR,
but recovery within 20 ms before discharge.
3. Persistent QRS-prolongation: QRS-prolongation >20 ms after TAVR
which persisted at least up to discharge.
Patients who developed a new bundle branch block after TAVRwere
specifically classified as transient or persistent QRS-prolongation de-
pending on whether it resolved before discharge or not.
2.2. Outcomes
The primary outcome for this study was the need for PPI. The re-
quirement for a permanent pacemaker was per treating physician's de-
cision and in compliance with the European Society of Cardiology
guidelines on cardiac pacing and cardiac resynchronization therapy.
2.3. Data analysis
Continuous variableswere presented asmean (±SD) ormedian (in-
terquartile range) and categorical variables as n (%). The distribution of
continuous variables was examined for normality through histograms
and Q-Q plots. To compare continuous variables between the three
different transcatheter heart valve designs one-way ANOVA and the
non-parametric Kruskal-Wallis test was performed, according to the
distribution of the variables. For categorical variables the Pearson χ2
test or the Fisher exact test as appropriate was performed. For ensuing
pairwise comparisons, the Bonferroni correction was used to account
for multiple testing. Cumulative pacemaker-free survival analysis was2
performed using the Kaplan-Meier method, with date of the TAVR pro-
cedure as initial time of follow-up (t=0). A log-rank testwas applied to
compare between-groupdifferences. Additionally, we performedmulti-
variable logistic regression to estimate the effect of the three separate
THV's on need for PPI at 30 days after TAVR. In this analysis we entered
THV type and added baseline covariates, based on selection of those co-
variates that displayed a difference with a p-value less than 0.10 in uni-
variate analysis.When limited number of eventswere present we chose
those covariates that had a p-value less than 0.10 and are known risk
factors for need for permanent pacemaker (i.e. male gender, depth of
implantation, RBBB at baseline). All statistical analyses were performed
with SPSS version 24.0 (IBM Corporation, New York, United States of
America). A two-sided value of p < 0.05 was considered statistically
significant.
3. Results
A total of 362 (54% male) patients who underwent TAVR with
CoreValve (N = 113), Evolut R (N = 157) or Evolut PRO (N = 92)
THV-design were included in the analysis after exclusion of cases with
an alternative access approach (Direct Aortic, N = 1), mortality within
72 h after the index procedure (N = 5), a pacemaker at baseline
(N= 37) or missing ECG data (N= 1). The overall median age and So-
ciety of Thoracic Surgeons (STS) predicted risk of mortality were 80
[73–84] years and 4.2% [2.8–6.3], respectively. TAVR was performed
through the transfemoral route in the majority (90%) of cases. All base-
line characteristics are displayed in Table 1. Half of all patients (59%)
had no conduction disturbances at baseline (Cohort A), while the re-
mainder presented with some kind of conduction abnormality, most
frequently a 1st degree atrioventricular block (AV1B, 74/362, 20%) or a
left bundle branch block (LBBB, 35/362, 10%) as displayed in Supple-
mentary Table 1.
3.1. Conduction dynamics with the three consecutive generations of SEV's
regardless of baseline conduction
Patients who underwent TAVR with Evolut R or PRO were treated
more often through a transfemoral route (CoreValve 84% vs. Evolut R
89% vs. Evolut PRO 97%, P = 0.001, Table 1). Implantation depth was
similar for the 3 different THVs (7.1 ± 3.2 mm vs. 7.0 ± 3.3 mm vs.
7.2 ± 2.6 mm, P = 0.87). Predilatation occurred more often with
Corevalve (80% vs. 8% vs. 12%), but post-dilatation less (28% vs. 42% vs.
41%). No significant differences were observed in prevalence of (func-
tional) bicuspid valves and calcification level in the left ventricular out
flow tract (LVOT) or annulus. Patients who underwent TAVR with
CoreValve had more often a LBBB at baseline (16% vs. 7% vs. 7%, P =
0.03), but presence of right bundle branch block (RBBB)was similar be-
tween three valves. The occurrence of new conduction disturbances
during the index procedure did not differ significantly between the
three self-expanding valves. However, thereafter new onset atrial fibril-
lation (AF) appeared more frequent with CoreValve (14% vs. 5% vs. 3%,
P = 0.004) and new permanent RBBB was more frequent with Evolut
PRO (0% vs. 1% vs. 7%, P = 0.001). Need for PPI tended to occur more
often with CoreValve (27% vs. 17% vs. 19%, P = 0.08, Table 2). Impor-
tantly, only three patients who underwent CoreValve TAVR with a
LBBB at baseline were in need for PPI. Kaplan Meier curves for the
pacemaker-free survival probability for the three transcatheter heart
valves are displayed in Supplementary Fig. 1 (Log-Rank test P =
0.073). In multivariable logistic regression analysis the use of Evolut R
(OR 0.38, 95% CI 0.19–0.78, P = 0.008) and PRO (OR 0.41, 95% CI
0.19–0.91, P-value = 0.028) were independently associated with
less need for PPI, also when corrected for depth of implantation,
conduction disturbances at baseline and male gender (Table 3).
Univariate analysis is displayed in Supplementary Table 2. Prevalence
of the three predefined conduction patterns did not differ between the
three THV-designs. However, CoreValve patients with persistent
Table 2









Permanent pacemaker post TAVR 31 (27%) 26 (17%) 17 (19%) 0.08
Due to AV3B 20 (65%) 23 (89%) 14 (82%)
Due to AV2B (Mobitz II) 3 (10%) 1 (4%) 3 (18%)
AF with bradycardia 3 (10%) 0 (0%) 0 (0%)
Sick sinus syndrome 3 (10%) 0 (0%) 0 (0%)
Other 2 (7%) 2 (8%) 0 (0%)
Mortality at 30 days 6 (5%) 3 (2%) 1 (1%) 0.13
New conduction disturbances
Per-procedural AV3B 23 (20%) 29 (19%) 15 (17%) 0.78
Per-procedural LBBB 63 (56%) 87 (55%) 51 (55%) 1.00
Per-procedural RBBB 2 (2%) 2 (1%) 0 (0%) 0.47
Temporary LBBB 36 (32%) 40 (26%) 30 (33%) 0.38
Permanent LBBB 34 (30%) 51 (33%) 29 (32%) 0.92
Temporary RBBB 4 (4%) 10 (6%) 2 (2%) 0.26
Permanent RBBB 0 (0%)† 1 (1%)‡ 6 (7%)†‡ 0.001
Temporary AV2B/AV3B 8 (7%) 10 (6%) 13 (14%) 0.09
Permanent AV2B/AV3B 19 (17%) 20 (13%) 11 (12%) 0.53
AV1B 22 (20%) 29 (19%) 15 (17%) 0.84
AF 16 (14%)†* 8 (5%)* 3 (3%)† 0.004
Categorical variables are shown as n (%). Continuous variables are displayed as mean ±
SD, median [interquartile range] or median, range. Abbreviations: AV3B = 3rd degree
atrioventricular block, AV2B= 2nd degree atrioventricular block, AF = Atrial fibrillation,
LBBB = left bundle branch block, RBBB = right bundle branch block, AV1B = 1st degree
atrioventricular block.
* (CoreValve vs. Evolut R), † (CoreValve vs. Evolut PRO), ‡ (Evolut R vs. Evolut PRO)means
P < 0.05 for pairwise comparisons with Bonferroni correction.
Table 3
Multivariable logistic regression analysis on need for permanent pacemaker implantation.








RBBB at baseline 13.68 (5.42–34.58) <0.005
AV1B at baseline 3.51 (1.75–7.02) <0.005
LAFB at baseline 1.21 (0.44–3.30) 0.71
Valve type
CoreValve 1.00 (reference) –
Evolut R 0.38 (0.19–0.78) 0.008
Evolut PRO 0.41 (0.19–0.91) 0.028
Depth of Implantation (mm) 1.22 (1.10–1.35) <0.005
Variables are shown as odds ratio OR (95% confidence interval). Abbreviations: RBBB =
Right Bundle Branch Block; AV1B = First Degree Atrioventricular Block; LAFB = Left An-
terior Fascicular Block.
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Male gender 67 (59%) 85 (54%) 42 (46%) 0.15

















Body mass index (kg/m2) 27 ± 4 27 ± 5 27 ± 5 0.82
Ischemic heart disease 52 (46%) 70 (45%) 31 (34%) 0.15
History of AVR/TAVR 5 (4%) 14 (9%) 7 (8%) 0.36
Diabetes mellitus 35 (31%) 43 (27%) 29 (32%) 0.73
Hypertension 84 (74%) 118 (76%) 71 (77%) 0.89
History of atrial fibrillation 28 (25%) 46 (29%) 22 (24%) 0.57
History of stroke 21 (19%) 17 (11%) 14 (15%) 0.19
Peripheral arterial disease 41 (36%) 79 (51%)‡ 27 (29%)‡ 0.002
NYHA class ≥3 82 (75%)* 91 (60%)* 62 (68%) 0.04
Bicuspid valve (functional) 9 (8%) 10 (7%) 7 (8%) 0.91
Moderate or severe annulus
calcification (Rosenhek)
90 (80%) 125 (82%) 77 (84%) 0.76
Moderate or severe LVOT
calcification
20 (18%) 22 (15%) 14 (15%) 0.82
Baseline conduction disturbances (alone or in combination)
RBBB 7 (6%) 15 (10%) 11 (12%) 0.35
LBBB 18 (16%) 11 (7%) 6 (7%) 0.03
UIVD 3 (3%) 3 (2%) 3 (3%) 0.80
AV1B 25 (22%) 28 (18%) 21 (23%) 0.56
LAFB 15 (13%) 12 (8%) 4 (4%) 0.07
LPFB 1 (1%) 1 (1%) 0 (0%) 0.68
Procedural details
Femoral access 95 (84%)† 140 (89%) 89 (97%)† 0.001
Depth of implantation (mm) 7.1 ± 3.2 7.0 ± 3.3 7.2 ± 2.6 0.87
Pre-dilatation 90 (80%)*† 12 (8%)* 11 (12%)† <0.001
Post-dilatation 32 (28%)* 66 (42%)* 38 (41%) 0.05








Valve in valve during procedure 7 (6%) 6 (4%) 4 (4%) 0.65







Categorical variables are shown as n (%). Continuous variables are displayed as mean ±
SD, median [interquartile range] or median, range. Abbreviations: STS = Society of Tho-
racic Surgeons, AVR = aortic valve replacement, TAVR = transcatheter aortic valve re-
placement, NYHA = New York Heart Association, LVOT = left ventricular outflow tract,
RBBB = right bundle branch block, LBBB = left bundle branch block, UIVD = unspecific
intraventricular conduction delay, AV1B = 1st degree atrioventricular block, LAFB = left
anterior fascicular block, LPFB = left posterior fascicular block.
* (CoreValve vs. Evolut R), † (CoreValve vs. Evolut PRO), ‡ (Evolut R vs. Evolut PRO)means
P < 0.05 for pairwise comparisons with Bonferroni correction.
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pared to the others (50% vs. 24% vs. 23%, P = 0.006).
3.2. Conduction dynamics between the THV-designs in Cohort A
In patients with normal conduction at baseline patient demo-
graphics were comparable between the three THV-designs (N = 214,
Supplementary Table 3). Patients treated with CoreValve were more
often male (53% vs. 48% vs. 30%, P = 0.03), had higher creatinine levels
(97 vs. 91 vs. 81 umol/L, P = 0.03) and more often underwent pre-
dilatation before valve deployment (80% vs. 8% vs. 14%, P < 0.0005).
The appearance of per-procedural conduction disturbances did not dif-
fer significantly, while new permanent RBBB occurred more often with
Evolut PRO compared to CoreValve and Evolut R (9% vs. 0% vs. 1%, P =
0.005). Implantation of CoreValve resulted in higher rates of PPI3
compared to Evolut R and PRO (25% vs. 6% vs. 11%, P = 0.002). The sta-
ble QRS-pattern was most frequently associated with Evolut R
(CoreValve 30% vs. Evolut R 42% vs. Evolut PRO 21%, P = 0.029). The
different conduction patterns correlated highly with the need for PPI
in patients with normal baseline conduction. Only patients with persis-
tent QRS-prolongation required PPI in cohort A, but less frequent with
Evolut R and PRO (50% vs. 13% vs. 17%, P = 0.001 overall, Fig. 1). Of
note, one patient with stable QRS-duration needed a permanent pace-
maker after discharge, when she was brought in the emergency room
with hyperkalemia and this was not considered as a QRS-pattern-
related pacemaker. In patients with transient QRS-prolongation the
QRS-width reached its maximum the same day of the procedure in
60% of patients, the next day in 73% and the 2nd day in 78% of patients,
cumulatively. All patients with transient prolongation reached their
maximum QRS-prolongation within 6 days after TAVR.
Fig. 1.Need for permanent pacemaker implantation related to conduction patterns post-TAVR between the THV-designs in Cohort A. Each column represents the total number of patients
with in red the number of patients who were in need of permanent pacemaker implantation. * One patient in Cohort A with stable QRS-duration required a permanent pacemaker after
discharge due to a total AV-blockwhen she suffered of hyperkalemia, whichwas not considered a device-related pacemaker for theQRS-patterns analysis. This pacemakerwas included in
the overall analysis. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Patients with abnormal conduction at baseline who underwent
TAVR with CoreValve had more pre-dilatation (79% vs. 7% vs. 8%,
P < 0.001) and less often transfemoral access (79% vs. 88% vs. 97%,
P = 0.04). No significant differences with regards to baseline con-
duction abnormalities, prevalence of (functional) bicuspid valves
and LVOT/annular calcifications were observed. Also, the occurrence
of per-procedural conduction disturbances between the three self-
expanding THVs were similar. Patients with CoreValve more often
developed atrial fibrillation after TAVR compared to those treated
with Evolut PRO. An equal number of patients required PPI (≈30%Fig. 2.Need for permanent pacemaker implantation related to conduction patterns post-TAVR b
with in red thenumber of patientswhowere inneedof permanent pacemaker implantation. (Fo
web version of this article.)
4
with all THV-designs, P = 0.90, Supplementary Table 4) in Cohort
B. Median recovery of transient QRS-prolongation was within 24 h
post TAVR in all groups. Conduction patterns did not predict need
for PPI with all three THV's in Cohort B (Fig. 2).
4. Discussion
Our study demonstrates that Evolut R and PRO are associated with
less need for PPI compared to CoreValve, particularly in patients with
normal conduction at baseline. Baseline conduction status and changing
QRS-patterns after TAVR have implications for a permanent pacemaker.
No PPI is required when QRS-width is normal at baseline and notetween the THV-designs in Cohort B. Each column represents the total number of patients
r interpretation of the references to colour in thisfigure legend, the reader is referred to the
H.G. Kroon, L. van Gils, F. Ziviello et al. Cardiovascular Revascularization Medicine xxx (xxxx) xxxpermanently affected after TAVR. Patients with normal baseline con-
duction and acquired permanent conduction abnormalities are at risk
for PPI, more so after Corevalve.
4.1. Conduction dynamics in perspective of conduction status at baseline
Overall, Evolut R and PRO were associated with a tendency towards
less PPI compared to Corevalve (17% vs. 19% vs. 27%, P = 0.08). These
lower pacemaker rates of 17% and 19% are comparable with numbers
currently reported in the literature for the newest generations of
Medtronic SEV's. Pacemaker rates vary from 12 to 20% for the Evolut R
and PRO and 25–30% with CoreValve [8–11,14–17]. Also, in multivari-
able logistic regression analysis Evolut R and PRO seemed associated
with less need for PPI compared to CoreValve, when correcting for
depth of implantation, male gender and baseline conduction abnormal-
ities. Themost important finding in this analysis is that patientswithout
baseline conduction disturbances and no newly acquired persistent
QRS-prolongation never needed a PPI regardless of the generation of
self-expanding THV. Previous studies mainly reported on the impact
of baseline variables to predict PPI post-TAVR like gender, baseline con-
duction status and THV-design [3–7]. We correlated baseline conduc-
tion status to periprocedural conduction dynamics in predicting the
risk of PPI after TAVR. Also, Toggweiler et al. reported the predictive
value of the ECG after TAVR and suggested that patients with no con-
duction disturbances post-TAVR never required PPI [12]. Patients who
developed a conduction disorder required extensive monitoring until
the 12 lead ECG was stable for 48 h after the index procedure [12]. We
refined this notion by adding dynamic QRS-patterns post-TAVR to pre-
dict theneed for PPI. Ourfindingsmay further elaborate on prior conclu-
sions because patients without baseline conduction abnormalities and
no or transient acquired QRS-prolongation never needed PPI. Only pa-
tients with newly acquired persistent conduction disorders were at
risk for a pacemaker. Those findings are in line with the recent study
conducted by our group in 300 patients treated with self-expanding
(1st generation), balloon expandable and mechanically expanded
THVs [13]. Similarly, patients with normal conduction at baseline and
no newly acquired persistent QRS-prolongation never required PPI.
The present study reinforces the importance of baseline conduction sta-
tus and peri-procedural conduction dynamics in predicting the need for
PPI with exclusively SEV THVs.
TAVR with Evolut R and PRO in patients with no conduction distur-
bances at baseline resulted in lower pacemaker rates (6% and 11%) as
compared to 25% with Corevalve. For all THV-designs the QRS-
patterns predicted the need for PPI in patients with normal conduction
at baseline. Patients were at risk for PPI if they acquired a persistent
QRS-prolongation. Of note, persistent prolongation could be distin-
guished from transient prolongationwithin 1 day post-TAVR in approx-
imately three-quarters of patients. In early TAVR experience therewas a
relationship between the occurrence of conduction disorders and bal-
loon pre-dilatation [18]. However, it remains questionable whether
less pre-dilatation in patients treated with the latest generations SEV's
could explain the lower PPI rate. Conversely, post-dilatation was per-
formed more frequently with the newer generations compared to
CoreValve. Also, in our study population, pre- and post-dilatation were
not associated with need for PPI.
Evolut R introduced partial repositionability and recapturability to
optimize valve deployment and implantation depth [19]. Of note we
did not find different implantation depths with the 3 THV designs.
Evolut R also featured amore consistent and homogeneous distribution
of the radial force which together with the redesigned inflow portion
may have less impact pressure on the left ventricular outflow tract
[19]. Its successor, the 3rd generation Evolut PRO was built on the
same principles and added an outer pericardial wrap to minimize
paravalvular leakage. Subsequent device iterations, increased TAVR ex-
perience, a trend for treating patients at lower risk for surgery and pro-
cedure modifications may have increased overall safety as well.5
Decision making regarding PPI after TAVR may have changed over
time. Still, high grade atrioventricular blocks remained the principle in-
dication for PPIwith all three valve types. Ourfindingsmay help identify
patients with SEV TAVR who could be eligible for safe early discharge
without the risk for (late) conduction disorders and need for PPI pro-
vided there was normal conduction at baseline. The QRS-patterns did
not correlate with need for PPI in patients with baseline conduction ab-
normalities. Those patients therefore require telemetrymonitoring for a
longer time to rule out progression to potentially lethal high-grade
atrioventricular block.
4.2. Study limitations
This was a single-center, observational study with inherent time
bias. Growing TAVR experience among operators and treating physi-
ciansmay have affected conduction dynamics (throughmature implan-
tation technique) and refined decision making related to permanent
pacemakers. Over time the relative proportion of alternative (non-
transfemoral) access and balloon valvuloplasty prior to TAVR declined.
The non-randomized, observational aspect of this study including the
implantation of the THV's in different timeperiods preclude anydefinite
conclusions. Our findings should be interpreted as hypothesis generat-
ing. Although decision for a permanent pacemaker was at the treating
physician's discretion, indications consisted predominantly of high de-
gree atrioventricular block and thus were according to the current
European Society of Cardiology guidelines on cardiac pacing. At our cen-
ter the temporary pacemaker is left in situ less than 1 day after the pro-
cedure. A permanent pacemaker was implanted when a patient was
pacemaker dependent 24 h after the index procedure. This may have
prevented resolution of conduction disorders before the decision to pro-
ceed with PPI. Overall, analyzable ECG's (without pacemaker interfer-
ence) were present for 68% of total hospitalized days at our center and
referral centers. Percentage of missing ECGs was lower with the newer
Evolut R and PRO valve, which may have resulted in underestimation
of the prevalence of high degree atrioventricular block in the CoreValve
cohort. Incompleteness of present ECG's reflects the retrospective anal-
ysis of current clinical practice, howevermissing ECG'swere equally dis-
tributed between our three predefined conduction patterns. Therefore
we think that our predefined conduction patterns are valid. Our study
with daily ECG's after TAVR represents one of the most extensive sam-
ples of conduction times reported to date.
5. Conclusion
Newer generation Evolut R and PRO were associated with
less PPI than Corevalve in present study. Acquired persistent
QRS-prolongation predicted PPI after TAVR only in patients
with normal conduction at baseline, and this finding was valid
regardless of the generation of SEV that was used. Our findings
may help identify eligible patients for early discharge after
Evolut R/PRO TAVR.
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